Aclarion, Inc. (ACONW) stock
ACONWNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACON
$0.02+0.00 (0.00%)
Close on Oct 30, 2026Market cap $5.62MP/E –Yield –
Aclarion r&d expenses
Research and development expenses are spending on new products and technology.
Aclarion's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.18M, up 28.5% year over year. For fiscal 2025 it was $1.03M, up 16.3% from the year before. The highest annual figure on record is $1.07M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03M | +16.3% |
| FY2024 | Dec 31, 2024 | $888.77K | +1.8% |
| FY2023 | Dec 31, 2023 | $873.34K | -18.2% |
| FY2022 | Dec 31, 2022 | $1.07M | +35.6% |
| FY2021 | Dec 31, 2021 | $787.85K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $297.07K | +9.8% |
| Q1 FY2026 | Mar 31, 2026 | $315.42K | +59.1% |
| Q4 FY2025 | Dec 31, 2025 | $263.13K | +4.5% |
| Q3 FY2025 | Sep 30, 2025 | $302.04K | +54.3% |
| Q2 FY2025 | Jun 30, 2025 | $270.43K | +33.8% |
| Q1 FY2025 | Mar 31, 2025 | $198.19K | -17.1% |
| Q4 FY2024 | Dec 31, 2024 | $251.83K | +14.1% |
| Q3 FY2024 | Sep 30, 2024 | $195.80K | -1.2% |
| Q2 FY2024 | Jun 30, 2024 | $202.10K | -19.2% |
| Q1 FY2024 | Mar 31, 2024 | $239.04K | +16.9% |
| Q4 FY2023 | Dec 31, 2023 | $220.68K | +0.8% |
| Q3 FY2023 | Sep 30, 2023 | $198.25K | -31.9% |
| Q2 FY2023 | Jun 30, 2023 | $250.01K | +37.3% |
| Q1 FY2023 | Mar 31, 2023 | $204.40K | -25.7% |
| Q4 FY2022 | Dec 31, 2022 | $219.00K | +34.6% |
| Q3 FY2022 | Sep 30, 2022 | $290.97K | +73.5% |
| Q4 FY2021 | Dec 31, 2021 | $182.10K | – |
| Q3 FY2021 | Sep 30, 2021 | $275.28K | – |
| Q2 FY2021 | Jun 30, 2021 | $162.71K | – |
| Q1 FY2021 | Mar 31, 2021 | $167.75K | – |